Access an exciting on-demand webinar where we dive into the latest therapeutic strategies leveraging the immune system to combat cancer, with a focus on immune checkpoint inhibitors and adoptive cell therapy. In this session our partner, BPS Bioscience showcase a powerful suite of innovative research tools driving breakthroughs in immuno-oncology, backed by real-world case studies.
What is this webinar about?
Discover how BPS Bioscience tools are accelerating the development of BCMA and CD19-targeted therapies, PD-1 neutralizing antibodies, and Fc-enhanced therapeutic antibodies.
Explore our biochemical assays, CRISPR gene-editing technologies, and co-culture functional assays, along with human immune cell kits for precise expansion and isolation of cell populations.
The speaker emphasized custom solutions and how their research tools can be fully customized to meet the specific needs of immuno-oncology research projects.
Webinar summary
Discover our partner BPS Bioscience and its solutions for immuno-oncology
• Come across latest advances in adoptive cell therapy and immune checkpoint modulation
• Uncover 2 cases studies for CD19 – BCMA targeted therapies, PD-1 antibodies development PD-1 neutralizing antibodies, and Fc-enhanced therapeutic antibodies.
• Find Custom solutions and services for immuno-oncology research
Q&A of the live session
-
Do I need to use a PD-L1/ TCR Activator expressing cell line to get a response in the PD-1 NFAT Cell Line, or a cell line expressing PD-L1 will be enough?
Yes of course - TBD
-
BPS offers both colorimetric and chemiluminescence assays for PD-1 binding to its ligand, what do you think are the main advantages/disadvantages of one format versus the other?
Yes of course TBD
-
What is the difference between a PD-1[Biotinylated}: PD-L1 Inhibitor and a PD-1:PD-L1[Biotinylated} inhibitor assay screen?
I don't know yet
Your webinar presenters
Veronique Baron, PhD
Associate Marketing Director
Dr. Véronique Baron, a cellular and molecular biologist with extensive experience in drug discovery, cell signaling, and cancer biology. Throughout her career Dr. Baron has worked with renowned research institutions, biotech companies, and has published numerous patents, scientific papers, grant review panels. She has contributed to drug development programs, including taking a candidate drug to clinical trials. Dr. Baron joined BPS Bioscience in 2021 as a Scientific Applications Manager and currently serves as Associate Director of Marketing.
Got questions? We are here to help!
Our team is ready to assist you with any inquiries. Reach out now and get the answers you need